Werewolf Therapeutics Stock Analysis
| HOWL Stock | USD 0.66 0.02 2.94% |
IPO Date 30th of April 2021 | 200 Day MA 1.1722 | 50 Day MA 0.7786 | Beta 0.779 |
Werewolf Therapeutics holds a debt-to-equity ratio of 0.119. At this time, Werewolf Therapeutics' Debt Ratio is quite stable compared to the past year. Werewolf Therapeutics' financial risk is the risk to Werewolf Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Werewolf Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Werewolf Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Werewolf Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Werewolf Therapeutics' stakeholders.
For many companies, including Werewolf Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Werewolf Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Werewolf Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 1.0844 | Enterprise Value Ebitda 0.5683 | Price Sales 52.2151 | Shares Float 41.2 M | Wall Street Target Price 5.2 |
Werewolf Therapeutics is fairly valued with Real Value of 0.65 and Target Price of 5.2. The main objective of Werewolf Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Werewolf Therapeutics is worth, separate from its market price. There are two main types of Werewolf Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Werewolf Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in child. Werewolf Stock Analysis Notes
About 42.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.08. Some equities with similar Price to Book (P/B) outperform the market in the long run. Werewolf Therapeutics recorded a loss per share of 1.62. The entity had not issued any dividends in recent years. Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the bodys immune system for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Werewolf Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. To learn more about Werewolf Therapeutics call Daniel Hicklin at 617 952 0555 or check out https://werewolftx.com.Werewolf Therapeutics Investment Alerts
| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics has some characteristics of a very speculative penny stock | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (50.48 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Insider Selling Werewolf Therapeutics Director Sells 20,942.28 in Stock |
Werewolf Largest EPS Surprises
Earnings surprises can significantly impact Werewolf Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-03 | 2024-03-31 | -0.35 | -0.39 | -0.04 | 11 | ||
2024-08-08 | 2024-06-30 | -0.38 | -0.43 | -0.05 | 13 | ||
2025-08-14 | 2025-06-30 | -0.47 | -0.4 | 0.07 | 14 |
Werewolf Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-06-30 | 328 K | Renaissance Technologies Corp | 2025-06-30 | 316.3 K | Alyeska Investment Group, L.p. | 2025-06-30 | 235.7 K | Goldman Sachs Group Inc | 2025-06-30 | 227.4 K | State Street Corp | 2025-06-30 | 119.2 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 103.8 K | Bridgeway Capital Management, Llc | 2025-06-30 | 102 K | Aqr Capital Management Llc | 2025-06-30 | 92.2 K | Y-intercept (hong Kong) Ltd | 2025-06-30 | 84.4 K | Ra Capital Management, Llc | 2025-06-30 | 6.7 M | Mpm Asset Management, Llc | 2025-06-30 | 4.3 M |
Werewolf Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.93 M.Werewolf Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.76) | (0.80) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | (0.86) | (0.91) |
Management Efficiency
Werewolf Therapeutics has return on total asset (ROA) of (0.4075) % which means that it has lost $0.4075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2243) %, meaning that it created substantial loss on money invested by shareholders. Werewolf Therapeutics' management efficiency ratios could be used to measure how well Werewolf Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.67. The value of Return On Capital Employed is expected to slide to -0.8. At this time, Werewolf Therapeutics' Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 17.5 M this year, although the value of Non Currrent Assets Other will most likely fall to about 349.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.52 | 2.77 | |
| Tangible Book Value Per Share | 1.52 | 2.77 | |
| Enterprise Value Over EBITDA | 0.15 | 0.14 | |
| Price Book Value Ratio | 1.00 | 0.95 | |
| Enterprise Value Multiple | 0.15 | 0.14 | |
| Price Fair Value | 1.00 | 0.95 | |
| Enterprise Value | -11.2 M | -10.7 M |
Effective management at Werewolf Therapeutics has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Technical Drivers
As of the 3rd of February, Werewolf Therapeutics maintains the Market Risk Adjusted Performance of (0.52), standard deviation of 7.21, and Mean Deviation of 4.68. Werewolf Therapeutics technical analysis makes it possible for you to employ past prices and volume data with the intention to determine a pattern that calculates the direction of the company's future prices. Please check out Werewolf Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Werewolf Therapeutics is priced fairly, providing market reflects its latest price of 0.66 per share. As Werewolf Therapeutics is a penny stock we also advise to confirm its jensen alpha numbers.Werewolf Therapeutics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Werewolf Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Werewolf Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Werewolf Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Werewolf Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Werewolf Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Werewolf Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Werewolf Therapeutics Outstanding Bonds
Werewolf Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Werewolf Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Werewolf bonds can be classified according to their maturity, which is the date when Werewolf Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Werewolf Therapeutics Predictive Daily Indicators
Werewolf Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Werewolf Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 36801.92 | |||
| Daily Balance Of Power | (0.20) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 0.68 | |||
| Day Typical Price | 0.67 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.02) | |||
| Relative Strength Index | 42.06 |
Werewolf Therapeutics Forecast Models
Werewolf Therapeutics' time-series forecasting models are one of many Werewolf Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Werewolf Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Werewolf Therapeutics Debt to Cash Allocation
Many companies such as Werewolf Therapeutics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Werewolf Therapeutics currently holds 37.09 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Werewolf Therapeutics has a current ratio of 4.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Werewolf Therapeutics' use of debt, we should always consider it together with its cash and equity.Werewolf Therapeutics Total Assets Over Time
Werewolf Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Werewolf Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Werewolf Therapeutics Debt Ratio | 28.0 |
Werewolf Therapeutics Corporate Bonds Issued
Werewolf Short Long Term Debt Total
Short Long Term Debt Total |
|
About Werewolf Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Werewolf Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Werewolf shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Werewolf Therapeutics. By using and applying Werewolf Stock analysis, traders can create a robust methodology for identifying Werewolf entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (43.02) | (40.87) | |
| Operating Profit Margin | (44.90) | (42.65) | |
| Net Loss | (43.02) | (40.87) | |
| Gross Profit Margin | 0.04 | 0.04 |
Current Werewolf Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Werewolf analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Werewolf analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 5.2 | Strong Buy | 6 | Odds |
Most Werewolf analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Werewolf stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Werewolf Therapeutics, talking to its executives and customers, or listening to Werewolf conference calls.
Werewolf Stock Analysis Indicators
Werewolf Therapeutics stock analysis indicators help investors evaluate how Werewolf Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Werewolf Therapeutics shares will generate the highest return on investment. By understating and applying Werewolf Therapeutics stock analysis, traders can identify Werewolf Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 155.6 M | |
| Long Term Debt | 26.1 M | |
| Common Stock Shares Outstanding | 43.9 M | |
| Total Stockholder Equity | 73.4 M | |
| Total Cashflows From Investing Activities | -254 K | |
| Property Plant And Equipment Net | 12.3 M | |
| Cash And Short Term Investments | 111 M | |
| Cash | 111 M | |
| Accounts Payable | 3 M | |
| Net Debt | -73.9 M | |
| 50 Day M A | 0.7786 | |
| Total Current Liabilities | 15.2 M | |
| Other Operating Expenses | 75.5 M | |
| Non Current Assets Total | 13.9 M | |
| Non Currrent Assets Other | 320 K | |
| Stock Based Compensation | 8.8 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in child. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.